Published in Neurology on November 12, 2008
Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimers Dement (2010) 4.85
Association of Insulin Resistance With Cerebral Glucose Uptake in Late Middle-Aged Adults at Risk for Alzheimer Disease. JAMA Neurol (2015) 3.58
Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 3.31
Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's. Proc Natl Acad Sci U S A (2010) 2.32
Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends Neurosci (2009) 2.16
Brain fuel metabolism, aging, and Alzheimer's disease. Nutrition (2010) 1.89
The Alzheimer's disease mitochondrial cascade hypothesis. J Alzheimers Dis (2010) 1.60
Mitochondrial haplotypes associated with biomarkers for Alzheimer's disease. PLoS One (2013) 1.47
White matter is altered with parental family history of Alzheimer's disease. Alzheimers Dement (2010) 1.45
Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer's disease. Alzheimers Dement (2011) 1.41
Reduced gray matter volume in normal adults with a maternal family history of Alzheimer disease. Neurology (2010) 1.41
Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.37
The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. Biochim Biophys Acta (2013) 1.34
Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. J Alzheimers Dis (2010) 1.28
Progressive regional atrophy in normal adults with a maternal history of Alzheimer disease. Neurology (2011) 1.23
Effects of ApoE4 and maternal history of dementia on hippocampal atrophy. Neurobiol Aging (2010) 1.22
Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer's disease. Antioxid Redox Signal (2011) 1.21
Amyloid burden and neural function in people at risk for Alzheimer's Disease. Neurobiol Aging (2013) 1.14
Perimenopause as a neurological transition state. Nat Rev Endocrinol (2015) 1.14
Role of family history for Alzheimer biomarker abnormalities in the adult children study. Arch Neurol (2011) 1.12
Maternal transmission of Alzheimer's disease: prodromal metabolic phenotype and the search for genes. Hum Genomics (2010) 1.12
Estrogen: a master regulator of bioenergetic systems in the brain and body. Front Neuroendocrinol (2013) 1.10
Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies. J Clin Neurol (2009) 1.06
Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions. Mol Aspects Med (2011) 1.05
Family history of Alzheimer's disease and hippocampal structure in healthy people. Am J Psychiatry (2010) 1.05
Impaired glycemia increases disease progression in mild cognitive impairment. Neurobiol Aging (2013) 1.05
Early detection of Alzheimer's disease using PiB and FDG PET. Neurobiol Dis (2014) 1.04
Reduced mitochondria cytochrome oxidase activity in adult children of mothers with Alzheimer's disease. J Alzheimers Dis (2011) 1.04
Hypometabolism in Alzheimer-affected brain regions in cognitively healthy Latino individuals carrying the apolipoprotein E epsilon4 allele. Arch Neurol (2010) 1.02
Cerebral blood flow is diminished in asymptomatic middle-aged adults with maternal history of Alzheimer's disease. Cereb Cortex (2012) 1.01
Oxidative stress and amyloid-beta pathology in normal individuals with a maternal history of Alzheimer's. Biol Psychiatry (2010) 0.98
Ovarian hormone loss induces bioenergetic deficits and mitochondrial β-amyloid. Neurobiol Aging (2011) 0.97
Assessing the progression of mild cognitive impairment to Alzheimer's disease: current trends and future directions. Alzheimers Res Ther (2010) 0.97
Mitochondria in neurodegeneration. Adv Exp Med Biol (2012) 0.97
Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents. Neurobiol Aging (2012) 0.96
Family history of Alzheimer disease predicts hippocampal atrophy in healthy middle-aged adults. Neurology (2012) 0.95
Structural brain changes in normal individuals with a maternal history of Alzheimer's. Neurobiol Aging (2011) 0.94
Beneficial network effects of methylene blue in an amnestic model. Neuroimage (2010) 0.94
Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease. Adv Pharmacol (2012) 0.93
Role of mitochondrial homeostasis and dynamics in Alzheimer's disease. Neurobiol Dis (2012) 0.93
An investigation of PreMCI: subtypes and longitudinal outcomes. Alzheimers Dement (2012) 0.92
Mitochondrial genomic analysis of late onset Alzheimer's disease reveals protective haplogroups H6A1A/H6A1B: the Cache County Study on Memory in Aging. PLoS One (2012) 0.92
Is brain amyloid production a cause or a result of dementia of the Alzheimer's type? J Alzheimers Dis (2010) 0.92
Glucose metabolism in normal aging and Alzheimer's disease: Methodological and physiological considerations for PET studies. Clin Transl Imaging (2013) 0.91
Role and treatment of mitochondrial DNA-related mitochondrial dysfunction in sporadic neurodegenerative diseases. Curr Pharm Des (2011) 0.90
Midlife predictors of Alzheimer's disease. Maturitas (2009) 0.89
Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention. Adv Pharmacol (2012) 0.89
Ketogenic diet in neuromuscular and neurodegenerative diseases. Biomed Res Int (2014) 0.89
Inhibition of glycolysis attenuates 4-hydroxynonenal-dependent autophagy and exacerbates apoptosis in differentiated SH-SY5Y neuroblastoma cells. Autophagy (2013) 0.88
Brain imaging of cognitively normal individuals with 2 parents affected by late-onset AD. Neurology (2014) 0.88
Ovariectomy induces a shift in fuel availability and metabolism in the hippocampus of the female transgenic model of familial Alzheimer's. PLoS One (2013) 0.86
White Matter Lipids as a Ketogenic Fuel Supply in Aging Female Brain: Implications for Alzheimer's Disease. EBioMedicine (2015) 0.86
FDG- and amyloid-PET in Alzheimer's disease: is the whole greater than the sum of the parts? Q J Nucl Med Mol Imaging (2011) 0.86
Consequences of Aberrant Insulin Regulation in the Brain: Can Treating Diabetes be Effective for Alzheimer's Disease. Curr Neuropharmacol (2011) 0.85
Amyloid burden, neuronal function, and cognitive decline in middle-aged adults at risk for Alzheimer's disease. J Int Neuropsychol Soc (2014) 0.85
Multi-resolution statistical analysis of brain connectivity graphs in preclinical Alzheimer's disease. Neuroimage (2015) 0.85
Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals. BMC Med (2012) 0.85
CREB regulates the expression of neuronal glucose transporter 3: a possible mechanism related to impaired brain glucose uptake in Alzheimer's disease. Nucleic Acids Res (2013) 0.85
Recent advances in imaging Alzheimer's disease. J Alzheimers Dis (2013) 0.85
Using biomarkers to improve detection of Alzheimer's disease. Neurodegener Dis Manag (2011) 0.84
Multimodal MRI neuroimaging biomarkers for cognitive normal adults, amnestic mild cognitive impairment, and Alzheimer's disease. Neurol Res Int (2011) 0.84
Maternal family history is associated with Alzheimer's disease biomarkers. J Alzheimers Dis (2012) 0.84
Family history and APOE-4 genetic risk in Alzheimer's disease. Neuropsychol Rev (2012) 0.83
Effects of hypertension and diabetes on sentence comprehension in aging. J Gerontol B Psychol Sci Soc Sci (2012) 0.83
Neurodegeneration and Alzheimer's disease (AD). What Can Proteomics Tell Us About the Alzheimer's Brain? Mol Cell Proteomics (2015) 0.82
Prevalence of Alzheimer's pathologic endophenotypes in asymptomatic and mildly impaired first-degree relatives. PLoS One (2013) 0.82
Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease. Mol Psychiatry (2016) 0.81
Nutrient patterns and brain biomarkers of Alzheimer's disease in cognitively normal individuals. J Nutr Health Aging (2015) 0.80
Targeting mitochondrial bioenergetics for Alzheimer's prevention and treatment. Curr Pharm Des (2011) 0.80
Pyruvate Dehydrogenase Kinases in the Nervous System: Their Principal Functions in Neuronal-glial Metabolic Interaction and Neuro-metabolic Disorders. Curr Neuropharmacol (2012) 0.80
Biomarkers in Alzheimer's disease. Front Neurol (2011) 0.79
Maternal age affects brain metabolism in adult children of mothers affected by Alzheimer's disease. Neurobiol Aging (2011) 0.79
FDG and Amyloid PET in Cognitively Normal Individuals at Risk for Late-Onset Alzheimer's Disease. Adv J Mol Imaging (2014) 0.78
Genetic variation in imprinted genes is associated with risk of late-onset Alzheimer's disease. J Alzheimers Dis (2015) 0.77
The concept of FDG-PET endophenotype in Alzheimer's disease. Neurol Sci (2011) 0.77
Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer's disease: a systematic review. BMC Geriatr (2016) 0.77
Let Food Be Thy Medicine: Diet, Nutrition, and Biomarkers' Risk of Alzheimer's Disease. Curr Nutr Rep (2015) 0.76
Mom and me: brain metabolism links Alzheimer disease to maternal genes. Neurology (2009) 0.75
Amelioration of cognitive impairments in APPswe/PS1dE9 mice is associated with metabolites alteration induced by total salvianolic acid. PLoS One (2017) 0.75
BACE1 activity impairs neuronal glucose oxidation: rescue by beta-hydroxybutyrate and lipoic acid. Front Cell Neurosci (2015) 0.75
Rat brain glucose transporter-2, insulin receptor and glial expression are acute targets of intracerebroventricular streptozotocin: risk factors for sporadic Alzheimer's disease? J Neural Transm (Vienna) (2017) 0.75
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology (1984) 119.59
Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature (2006) 15.69
The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry (1982) 10.83
Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging (1997) 10.81
Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol (1997) 10.06
Comparing functional (PET) images: the assessment of significant change. J Cereb Blood Flow Metab (1991) 4.69
A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med (1995) 4.44
Mitochondrial abnormalities in Alzheimer's disease. J Neurosci (2001) 4.39
Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 4.26
Multi-infarct dementia. A cause of mental deterioration in the elderly. Lancet (1974) 3.91
Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage (2002) 3.88
Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A (2001) 3.86
Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging (2003) 3.50
Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA (2002) 3.16
A validation study of the Dementia Questionnaire. Arch Neurol (1994) 2.89
Cybrids in Alzheimer's disease: a cellular model of the disease? Neurology (1997) 2.85
Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study. Genet Med (2004) 2.82
New norms for a new generation: cognitive performance in the framingham offspring cohort. Exp Aging Res (2004) 2.75
Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proc Natl Acad Sci U S A (2007) 2.41
Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann Neurol (2003) 2.26
Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology (2005) 2.24
Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. J Nucl Med (2006) 2.17
Glucose metabolic rate kinetic model parameter determination in humans: the lumped constants and rate constants for [18F]fluorodeoxyglucose and [11C]deoxyglucose. J Cereb Blood Flow Metab (1985) 1.96
Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging (2007) 1.90
Energy hypometabolism in posterior cingulate cortex of Alzheimer's patients: superficial laminar cytochrome oxidase associated with disease duration. J Neurosci (2001) 1.88
Abnormal mitochondrial morphology in sporadic Parkinson's and Alzheimer's disease cybrid cell lines. Exp Neurol (2000) 1.80
Variability of familial risk of Alzheimer disease across the late life span. Arch Gen Psychiatry (2005) 1.63
Increased risk of dementia in mothers of Alzheimer's disease cases: evidence for maternal inheritance. Neurology (1996) 1.59
(18)F-FDG PET database of longitudinally confirmed healthy elderly individuals improves detection of mild cognitive impairment and Alzheimer's disease. J Nucl Med (2007) 1.23
Leukoencephalopathy in normal and pathologic aging: 2. MRI of brain lucencies. AJNR Am J Neuroradiol (1986) 1.18
Variability of age at onset in siblings with familial Alzheimer disease. Arch Neurol (2007) 1.15
Genetic epidemiological study of maternal and paternal transmission of Alzheimer's disease. Am J Med Genet (1999) 1.09
Quantitation of the human basal ganglia with positron emission tomography: a phantom study of the effect of contrast and axial positioning. IEEE Trans Med Imaging (1991) 1.02
The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry (1982) 10.83
Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA (2001) 5.13
Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology (2007) 3.97
Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A (2001) 3.86
Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med (1997) 3.71
The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience (2000) 3.40
Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging (2001) 3.25
Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging (2005) 3.00
Atrophy of the medial occipitotemporal, inferior, and middle temporal gyri in non-demented elderly predict decline to Alzheimer's disease. Neurobiol Aging (2000) 2.80
Frequency of hippocampal formation atrophy in normal aging and Alzheimer's disease. Neurobiol Aging (1997) 2.68
Specific hippocampal volume reductions in individuals at risk for Alzheimer's disease. Neurobiol Aging (1997) 2.66
Hippocampal damage and memory impairments as possible early brain complications of type 2 diabetes. Diabetologia (2007) 2.60
Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease. Ann Neurol (1998) 2.48
The radiologic prediction of Alzheimer disease: the atrophic hippocampal formation. AJNR Am J Neuroradiol (1993) 2.44
Hippocampal volume losses in minimally impaired elderly. Lancet (1995) 2.26
Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology (2005) 2.24
Global Deterioration Scale (GDS). Psychopharmacol Bull (1988) 2.14
Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann N Y Acad Sci (2007) 2.11
Altered glucose metabolism in microvessels from patients with Alzheimer's disease. Ann Neurol (1989) 2.08
Early marker for Alzheimer's disease: the atrophic hippocampus. Lancet (1989) 2.02
Alzheimer disease: measuring loss of cerebral gray matter with MR imaging. Radiology (1991) 1.92
Disease progression in a cohort of infants with vertically acquired HIV infection observed from birth: the Women and Infants Transmission Study (WITS). J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.88
MRI of entorhinal cortex in mild Alzheimer's disease. Lancet (1999) 1.86
MRI and CSF studies in the early diagnosis of Alzheimer's disease. J Intern Med (2004) 1.77
Localization of muscle gene products in nuclear domains. Nature (1989) 1.75
Hepatic 'stem cell' malignancies in adults: four cases. Histopathology (2003) 1.73
Relationships between regional neuronal loss and neurofibrillary changes in the hippocampal formation and duration and severity of Alzheimer disease. J Neuropathol Exp Neurol (1997) 1.67
CT diagnostic features of Alzheimer disease: importance of the choroidal/hippocampal fissure complex. AJNR Am J Neuroradiol (1990) 1.62
Hippocampal atrophy in normal aging. An association with recent memory impairment. Arch Neurol (1993) 1.49
Longitudinal CSF isoprostane and MRI atrophy in the progression to AD. J Neurol (2007) 1.41
Volumetric analysis of the pre-frontal regions: findings in aging and schizophrenia. Psychiatry Res (2001) 1.38
Biliary papillary neoplasm of the liver. Histol Histopathol (2002) 1.38
Hippocampal atrophy in early Alzheimer's disease: anatomic specificity and validation. Psychiatr Q (1993) 1.33
Hippocampal formation size predicts declining memory performance in normal aging. Neurology (1996) 1.33
Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease. Pathophysiologic implications. Arch Neurol (1992) 1.33
Hippocampal formation size in normal human aging: a correlate of delayed secondary memory performance. Learn Mem (1999) 1.31
Atrophy rate in medial temporal lobe during progression of Alzheimer disease. Neurology (2004) 1.31
Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology (2012) 1.31
Obstetric and newborn outcomes in a cohort of HIV-infected pregnant women: a report of the women and infants transmission study. J Acquir Immune Defic Syndr Hum Retrovirol (1999) 1.20
Cortisol differentially affects memory in young and elderly men. Behav Neurosci (2001) 1.19
Leukoencephalopathy in normal and pathologic aging: 2. MRI of brain lucencies. AJNR Am J Neuroradiol (1986) 1.18
Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment. Neurosci Lett (2002) 1.14
Computed tomography and positron emission transaxial tomography evaluations of normal aging and Alzheimer's disease. J Cereb Blood Flow Metab (1983) 1.13
MRI volume of the amygdala: a reliable method allowing separation from the hippocampal formation. Psychiatry Res (1999) 1.13
Positron emission tomographic studies of aging and Alzheimer disease. AJNR Am J Neuroradiol (1983) 1.13
Small fiber dysfunction predominates in Fabry neuropathy. J Clin Neurophysiol (2002) 1.13
Neuronal and volume loss in CA1 of the hippocampal formation uniquely predicts duration and severity of Alzheimer disease. Brain Res (1998) 1.12
Treatment interruption after pregnancy: effects on disease progression and laboratory findings. Infect Dis Obstet Gynecol (2009) 1.09
Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy. Neurology (2004) 1.05
Cortisol reduces hippocampal glucose metabolism in normal elderly, but not in Alzheimer's disease. J Clin Endocrinol Metab (1997) 1.04
Hyper IgM immunodeficiency. A primary dysfunction of B lymphocyte isotype switching. J Clin Invest (1983) 1.01
Documentation of Epstein-Barr virus infection in immunodeficient patients with life-threatening lymphoproliferative diseases by clinical, virological, and immunopathological studies. Cancer Res (1981) 1.01
Positron emission tomography and computed tomography assessments of the aging human brain. J Comput Assist Tomogr (1984) 1.00
Volumetric measurement of the hippocampus, the anterior cingulate cortex, and the retrosplenial granular cortex of the rat using structural MRI. Brain Res Brain Res Protoc (2002) 0.99
Blood culture in the first 6 months of life for the diagnosis of vertically transmitted human immunodeficiency virus infection. The Women and Infants Transmission Study Group. J Infect Dis (1994) 0.99
Abnormal cortisol response in Alzheimer's disease linked to hippocampal atrophy. Lancet (1988) 0.98
Reduced incidence of left-handedness in clinically diagnosed dementia of the Alzheimer type. Neurobiol Aging (1986) 0.98
Duration of neurofibrillary changes in the hippocampal pyramidal neurons. Brain Res (1998) 0.97
Atrophy of hippocampal formation subdivisions correlates with stage and duration of Alzheimer disease. Dementia (1995) 0.97
Central amine metabolism in Alzheimer's disease: in vivo relationship to cognitive deficit. Neurobiol Aging (1981) 0.97
Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma. Histopathology (1999) 0.95
Pustulosis palmaris et plantaris: its association with chronic recurrent multifocal osteomyelitis. J Am Acad Dermatol (1985) 0.94
A phenotypic study of CD8+ lymphocyte subsets in infants using three-color flow cytometry. Clin Immunol Immunopathol (1994) 0.93
Leukoencephalopathy in normal and pathologic aging: 1. CT of brain lucencies. AJNR Am J Neuroradiol (1986) 0.92
Mortality and temporal course of probable Alzheimer's disease: a 5-year prospective study. Int Psychogeriatr (1996) 0.92
Measurement of medial temporal lobe atrophy in diagnosis of Alzheimer's disease. Lancet (1993) 0.92
Age-related changes in brain: II. Positron emission tomography of frontal and temporal lobe glucose metabolism in normal subjects. Psychiatr Q (1995) 0.92
Vascular fibrosis and calcification in the hippocampus in aging, Alzheimer disease, and Down syndrome. Acta Neuropathol (2001) 0.90
Immune response to influenza vaccination in community-dwelling Chinese elderly persons. Vaccine (2006) 0.90
Volumetric structural magnetic resonance imaging (MRI) of the rat hippocampus following kainic acid (KA) treatment. Brain Res (2002) 0.90
Early detection of Alzheimer's disease with PET imaging. Neurodegener Dis (2010) 0.90
Relevance of postmortem radiology to the diagnosis of fatal cerebral gas embolism from compressed air diving. J Clin Pathol (2006) 0.89
The stage specific temporal course of Alzheimer's disease: functional and behavioral concomitants based upon cross-sectional and longitudinal observation. Prog Clin Biol Res (1989) 0.89
Correlations between computerised tomographic changes and behavioural deficits in senile dementia. Lancet (1979) 0.89